NEW YORK, Feb. 27, 2018 -- Global Chronic Idiopathic Constipation (CIC) Drugs Market is estimated to reach $2.96 billion by 2024 Says, Profshare Market Research; growing at a CAGR of 6.6% between 2016 and 2024.If the constipation happens chronically with an unidentifiable cause it is known as Chronic Idiopathic Constipation (CIC). The word “Idiopathic” means the cause is not known. Increasing awareness and widespread presence of idiopathic constipation are the key factors for growth of CIC drugs market. Currently CIC drugs market has huge opportunity for research and development.
Depending on type of drugs, global CIC drugs market is segmented into Lubiprostone, Linaclotide and others. Currently Lubiprostone drug segment dominates the market. But, due to its lower efficacy in comparison with others, patent loss and growing competition from Linaclotide, Lubiprostone will lose its dominance in the upcoming future. Depending on prescription types it is subdivided into prescribed drugs and over the counter drugs. After analysing the symptoms also, constipation is not considered as a disease but a condition, side effect or syndrome. Usually patients avoid to visit doctors to address the issue. Therefore approximately 65% of the CIC drugs market is covered by over the counter drugs. The top players of CIC drugs market are Actavis, Chugai Pharmaceutical, Ferring International Center S.A., Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding AG, Sanofi, Bayer AG, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc, Ironwood Pharmaceuticals and Progenics Pharmaceuticals.
Get Free Sample: https://www.profsharemarketresearch.com/sample/chronic-idiopathic-constipation-cic-drugs-market-sample/
Global Chronic Idiopathic Constipation (CIC) Drugs Market: End Users/Application Analysis
- Hospitals & Clinics
- Ambulatory Surgical Centres
- Long Term Care Centres
Global Chronic Idiopathic Constipation (CIC) Drugs Market: Product Type
- Lubiprostone
- Linaclotide
Report Enquiry: https://www.profsharemarketresearch.com/enquiry/chronic-idiopathic-constipation-cic-drugs-market-enquiry/
Global Chronic Idiopathic Constipation (CIC) Drugs Market: Competitive Analysis
Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Chronic Idiopathic Constipation (CIC) Drugs:
- Actavis
- Chugai Pharmaceutical
- Ferring International Center S.A.
- Synergy Pharmaceuticals
- Pfizer
- GlaxoSmithKline
- Roche Holding AG
- Sanofi
- Bayer AG
- Salix Pharmaceuticals Ltd
- Sucampo Pharmaceuticals Inc
- Ironwood Pharmaceuticals
- Progenics Pharmaceuticals
Buy Report: https://www.profsharemarketresearch.com/buy/chronic-idiopathic-constipation-cic-drugs-market-buy-su/
Contact Us:
Mia Cox,
Email- [email protected]
Tel- 1-877-797-7295
www.profsharemarketresearch.com


Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Washington Post Publisher Will Lewis Steps Down After Layoffs
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 



